Last updated 27 August 2026 · Originally published 14 March 2020
CB1 and CB2 receptors are the two main cannabinoid receptors, and the principal places where THC meets your body. They are docking points on the surface of your cells, discovered around 1990 when researchers went looking for how THC does what it does. They are not the only targets of cannabis compounds, but they are the core, and the answer turned out to be bigger than cannabis: your body has a whole signalling system built around these receptors, and the plant’s compounds work — or don’t — depending on how they fit it.
The system the receptors belong to
A receptor is a lock. It sits on a cell and waits for the right molecule to come along and turn it, and when that happens the cell changes what it is doing. Your body would not build locks for a plant’s benefit, so the discovery of CB1 and CB2 raised an obvious question: where are the body’s own keys?
They were found within a few years. The best known are anandamide and 2-AG, molecules your body makes on demand, uses locally, and clears away quickly with dedicated enzymes. Together — the receptors, the body’s own cannabis-like molecules, and the enzymes that make and remove them — this is the endocannabinoid system. In many brain circuits it works like a dimmer switch: when a receiving nerve cell is strongly activated, it releases endocannabinoids backwards across the junction, telling the sending cell to quieten down. That is why the system touches so many things — pain, appetite, mood, memory, sleep, inflammation — without being “for” any one of them. We cover the idea that some people’s system runs low in our article on endocannabinoid deficiency.
CB1: mostly the brain
CB1 is one of the most common receptors in the brain, and it is also scattered more thinly through the rest of the body. When THC reaches the brain, it fits the CB1 lock well enough to turn it. Unlike the body’s own endocannabinoids, which are made locally and cleared in moments, THC circulates through the brain and body for hours. Turning CB1 produces the high, and explains most of THC’s intoxicating effects: the hunger, the altered sense of time, the fogged short-term memory.
CB2: mostly the immune system
CB2 lives mainly on immune cells, in the spleen and other immune tissue, with smaller amounts elsewhere. Activating it changes immune signalling, and in laboratory and animal studies that is often anti-inflammatory, which is why it attracts researchers — and why so much cannabinoid marketing gestures at it. Because there is relatively little CB2 in the brain circuits responsible for intoxication, compounds acting selectively on CB2 should not cause a high. Drug companies have spent two decades trying to turn all this into anti-inflammatory medicines, and no selective CB2 medicine has yet been approved — which is worth remembering when a supplement claims to have solved what they could not.
Where CBD fits, and where it doesn’t
Here is the part that surprises people: CBD does not activate CB1 or CB2 in the straightforward way THC activates CB1. It binds poorly to their main sites, so direct activation of either receptor is unlikely to explain most of its effects. That is a major reason pure CBD does not produce a THC-like high — and why “CBD works on your cannabinoid receptors”, a line on half the product pages ever written, is misleading at best.
What CBD may do instead is influence the system indirectly. In cell studies it can alter CB1’s signalling from a separate site on the receptor, although that does not mean it reliably cancels THC’s effects in people. It may also affect how anandamide is transported or broken down, though that mechanism remains disputed. And it interacts with numerous targets outside the endocannabinoid system, including a serotonin receptor and channels involved in pain and temperature sensing. Which of these interactions matter at the doses people actually reach is uncertain. A long list of possible targets may make CBD sound versatile, but it is not evidence that CBD treats a long list of conditions.
What mechanism can and cannot tell you
These are genuine areas of pharmacological research, though much of the detailed evidence comes from cells and animals and some mechanisms remain disputed. They explain a lot: why THC intoxicates and CBD does not, why the plant affects so many systems at once, why immune effects are plausible. What none of it does is show that any product treats anything. Activating a receptor is not automatically beneficial: the result depends on where the receptor is, how strongly it is activated, and for how long. “It acts on receptor X” is the beginning of a research programme, not the end of one, and the history of medicine is full of beautiful mechanisms that failed in trials.
So treat receptor talk on a label as decoration. What matters is what happened when the compound was given to people, and for that we keep separate, condition-by-condition articles: anxiety, pain, and sleep are the places to start. The receptors explain much of how THC works. Whether cannabis or CBD works for a particular condition is a different question, and trials — not receptor diagrams — answer it.
Nothing in this article is medical advice.
